ZFHX4 and neoplasm: Studies by Petrelli et al. (2020) and Mao et al. (2023) identify mutations in genes such as USH2A, ZFHX4, and PLCO as being highly correlated with enhanced tumor immunogenicity and improved outcomes with ICIs [19,21].